{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:04:09Z","timestamp":1785535449029,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jcyt.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:49:45Z","timestamp":1625474985000},"page":"902-907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate"],"prefix":"10.1016","volume":"23","author":[{"given":"Lassina","family":"Barro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Delila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouada","family":"Nebie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayasu","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Burnouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2021.05.006_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0002","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/trf.15581","article-title":"Strategies toward virus and prion safe human platelet lysates","volume":"60","author":"Blumel","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.102674","article-title":"Viral safety of human platelet lysate for cell therapy and regenerative medicine: moving forward, yes, but without forgetting the past","volume":"58","author":"Burnouf","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1022969101804","article-title":"Virus contaminations of cell cultures\u2014a biotechnological view","volume":"39","author":"Merten","year":"2002","journal-title":"Cytotechnology"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0005","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1007\/s00253-013-5451-3","article-title":"Implementing high-temperature short-time media treatment in commercial-scale cell culture manufacturing processes","volume":"98","author":"Pohlscheidt","year":"2014","journal-title":"Applied microbiology and biotechnology"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0006","first-page":"20","article-title":"Virus Risk Mitigation in Cell Culture Media","volume":"29","author":"Manzke","year":"2016","journal-title":"BioPharm International"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0007","doi-asserted-by":"crossref","first-page":"P22","DOI":"10.1186\/1753-6561-9-S9-P22","article-title":"Protection of bioreactor culture from virus contamination by use of a virus barrier filter","volume":"9","author":"Mann","year":"2015","journal-title":"BMC Proc"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0008","article-title":"Supplement: Upstream Virus Safety: Protect Your Bioreactor by Media Filtration","volume":"37","author":"Carbrello","year":"2017","journal-title":"Genetic Engineering & Biotechnology News"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.biomaterials.2015.10.065","article-title":"Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?","volume":"76","author":"Burnouf","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09537104.2020.1849602","article-title":"Human platelet lysates for human cell propagation","volume":"32","author":"Barro","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jcyt.2020.04.099","article-title":"Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells","volume":"22","author":"Barro","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0012","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/btpr.2694","article-title":"Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration","volume":"34","author":"Cetlin","year":"2018","journal-title":"Biotechnology progress"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0013","doi-asserted-by":"crossref","first-page":"e2921","DOI":"10.1002\/btpr.2921","article-title":"Using a noninfectious MVM surrogate for assessing viral clearance during downstream process development","volume":"36","author":"Orchard","year":"2020","journal-title":"Biotechnology progress"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0014","doi-asserted-by":"crossref","first-page":"498","DOI":"10.5731\/pdajpst.2018.009142","article-title":"Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies","volume":"72","author":"Schwantes","year":"2018","journal-title":"PDA journal of pharmaceutical science and technology"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pep.2016.09.002","article-title":"Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa","volume":"129","author":"Ellgaard","year":"2017","journal-title":"Protein expression and purification"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rinim.2012.01.002","article-title":"Effective virus inactivation and removal by steps of Biotest Pharmaceuticals IGIV production process","volume":"2","author":"Dichtelm\u00fcller","year":"2012","journal-title":"Results in immunology"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tibtech.2019.06.002","article-title":"Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion","volume":"38","author":"Schallmoser","year":"2020","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41587-020-0507-2","article-title":"Viral contamination in biologic manufacture and implications for emerging therapies","volume":"38","author":"Barone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0019","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.hoc.2019.05.001","article-title":"Pathogen Reduction: The State of the Science in 2019","volume":"33","author":"Gehrie","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tracli.2018.07.001","article-title":"Pathogen inactivation\/reduction technologies for platelet transfusion: where do we stand?","volume":"25","author":"Garraud","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0021","first-page":"44","article-title":"Variables affecting titer and long-term stability of virus stocks: xenotropic murine leukemia and mouse minute viruses","volume":"6","author":"Romanowski","year":"2008","journal-title":"BioProcess International"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0022","series-title":"Process Scale Bioseparations for the Biopharmaceutical Industry","author":"Shukla","year":"2006"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2014.07.005","article-title":"The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates","volume":"28","author":"Kaiser-Guignard","year":"2014","journal-title":"Blood Reviews"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0024","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/trf.15251","article-title":"A double-virally-inactivated (intercept\u2013solvent\/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells","volume":"59","author":"Barro","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nbt.2018.11.003","article-title":"Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells","volume":"49","author":"Chen","year":"2019","journal-title":"New biotechnology"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.biomaterials.2017.07.018","article-title":"Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease","volume":"142","author":"Chou","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0027","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcyt.2016.04.002","article-title":"Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion","volume":"18","author":"Kao","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0029","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/trf.16022","article-title":"Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years\u2019 experience of the plasma protein manufacturers","volume":"60","author":"Roth","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biologicals.2013.10.003","article-title":"Robustness of nanofiltration for increasing the viral safety margin of biological products","volume":"42","author":"Caballero","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.memsci.2005.10.057","article-title":"Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova\u00ae 20N","volume":"278","author":"Hongo-Hirasaki","year":"2006","journal-title":"Journal of membrane science"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0032","doi-asserted-by":"crossref","first-page":"e2875","DOI":"10.1002\/btpr.2875","article-title":"Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: impact of membrane structure and localization of captured virus particles","volume":"35","author":"Adan-Kubo","year":"2019","journal-title":"Biotechnology progress"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0033","first-page":"481","article-title":"Adventitious Viruses Detected in Biopharmaceutical Bulk Harvest Samples over a 10 Year Period","volume":"64","author":"Kerr","year":"2010","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.jcyt.2021.05.006_bib0034","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00063030-200519020-00002","article-title":"Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens","volume":"19","author":"Cai","year":"2005","journal-title":"BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921006861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921006861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:43:30Z","timestamp":1761443010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324921006861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1465324921006861"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.05.006","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}